Can-Fite BioPharma share price logo

Can-Fite BioPharma

AMEX: CANF

$1.63

+0.01

(+0.62%)

as on

Can-Fite BioPharma Stock Performance

as on November 3, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.61
    $1.66
    downward going graph

    1.23%

    Downside

    1.84%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.60
    $12.30
    downward going graph

    1.84%

    Downside

    654.60%

    Upside

    downward going graph

Can-Fite BioPharma share price movements today

Previous Close
$1.62
Open
$1.62
Volume
551.2K
Market Cap
$4.9M
Day's Low - High
$1.61 - $1.66
52 Week Low - High
$1.60 - $12.30

Can-Fite BioPharma Historical Returns

1 Month Return
-25.3 %
3 Month Return
-48.58 %
1 Year Return
-80.21 %
3 Year Return
-96.25 %
5 Year Return
-99.45 %

Can-Fite BioPharma Stock Fundamentals & Key Indicators

Check Can-Fite BioPharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.9M

EPS (TTM)

-1.2552

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.23

Industry PE ratio

-3.84

PEG Ratio

0.00

EBITDA

-9.7M

Revenue (TTM)

405.0K

Profit Margin

100.00%

Return On Equity TTM

-182.89%

Can-Fite BioPharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Can-Fite BioPharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Can-Fite BioPharma image
Can-Fite BioPharma
Buy$4.9M-99.45%-0.23100.00%0.00%
Moderna image
Moderna
Neutral$88.5B-36.16%-27.78-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$141.7B192.56%32.2786.04%0.00%
Regeneron image
Regeneron
Buy$95.5B47.41%19.7685.77%0.40%

Stock Returns calculator for Can-Fite BioPharma Stock including INR - Dollar returns

The Can-Fite BioPharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Can-Fite BioPharma investment value today

Current value as on today

₹21,169

Returns

-₹78,831

(-78.83%)

Returns from Can-Fite BioPharma Stock

-₹80,209 (-80.21%)

Dollar Impact

₹1,378 (+1.38%)

Analyst Recommendation on Can-Fite BioPharma Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Can-Fite BioPharma. Average target price of $8

Can-Fite BioPharma Share Price Target

Get share price movements and forecasts by analysts on Can-Fite BioPharma.

Current Price

$1.63

Analyzed by

1 Analysts

High

$8

0

Low

$8

Can-Fite BioPharma target price $0, a slight upside of 0% compared to current price of $1.63. According to 1 analysts rating.

Indian Investors' Interest in Can-Fite BioPharma Stock

Search interest for Can-Fite BioPharma Stock has decreased by -61% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-61% versus previous 30 day period

Can-Fite BioPharma Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-1
-2
-2
-2
-2
-2
-2
-2
-2
-2
EBITDA
-1
-2
-2
-2
-2
-2
-2
-2
-2
-2
Interest Expense
0
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-1
-1
-1
-1
-2
-2
-2
-2
-2
-2
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-1
-1
-1
-1
-2
-2
-2
-2
-2
-2
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%

Can-Fite BioPharma Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Mar 2025
Dec 2025
Total Revenue
3
2
0
0
0
0
0
0
Gross Profit
3
2
0
0
0
0
0
0
Operating Income
-5
-12
-14
-12
-10
-8
-8
-10
EBITDA
-6
-11
-14
-12
-10
-8
-8
-10
Interest Expense
1
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
Income Before Tax
-6
-12
-14
-12
-10
-7
-7
-9
Income Tax Expense
0
0
-
0
0
-
-
-
Net Income
-6
-12
-14
-12
-10
-7
-7
-9
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
94.07%

Can-Fite BioPharma Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-1
-1
-1
-1
-2
-2
-2
-2
-2
-2
Operating Cash Flow
-
-2
-2
-1
-2
-2
-2
-2
-2
-2
Investing Cash Flow
-
2
2
-1
1
1
-1
-1
0
0
Financing Cash Flow
-
-
-
3
1
1
3
3
1
1
Change in Cash
-
-
4
-4
-
-
-
-
-
-

Can-Fite BioPharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Mar 2025
Dec 2025
Net Income
-4
-6
-12
-14
-12
-10
-7
-7
-9
Operating Cash Flow
-9
-4
-10
-12
-9
-10
-8
-7
-9
Investing Cash Flow
0
0
0
0
-14
9
0
1
0
Financing Cash Flow
4
4
10
17
20
-
9
6
9
Change in Cash
-5
0
0
5
-3
-1
1
0
0

Can-Fite BioPharma News & Key Events

  • img

    Today's Timeline - 02 September

    Wed, 05:11 PM

    -

    Can-Fite reports longer-than-anticipated survival in Namodenoson study for advanced hepatocellular carcinoma, considering earlier interim analysis.

Insights on Can-Fite BioPharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -2.47M → -2.30M (in $), with an average increase of 3.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 184.8% return, outperforming this stock by 281.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 786.5% return, outperforming this stock by 866.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 101.5K → 101.0K (in $), with an average decrease of 0.3% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, CANF stock has moved down by -48.6%

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
OrganisationCan-Fite BioPharma
Headquarters26 Ben Gurion Street, Ramat Gan, 5257346, IL
IndustryBiotechnology
CEOMotti Farbstein

Key Management of Can-Fite BioPharma

Name

Title

Mr. Motti Farbstein

CEO, CFO, Financial & Operating Officer

Dr. Sari Fishman Ph.D.

Vice President of Business Development

Dr. Stephen A. Harrison FACP, M.D.

Member of Clinical Advisory Board & Consulting Chief Medical Officer

Dr. Pnina Fishman Ph.D.

Founder, Chief Scientific Officer & Executive Chairperson

FAQs

What is Can-Fite BioPharma share price today?

Can-Fite BioPharma share price today is $1.63 as on at the close of the market. Can-Fite BioPharma share today touched a day high of $1.66 and a low of $1.61.

What is the 52 week high and 52 week low for Can-Fite BioPharma share?

Can-Fite BioPharma share touched a 52 week high of $12.30 on and a 52 week low of $1.60 on . Can-Fite BioPharma stock price today i.e. is closed at $1.63,which is 86.75% down from its 52 week high and 1.87% up from its 52 week low.

What is Can-Fite BioPharma's market capitalisation today?

Can-Fite BioPharma market capitalisation is $0.00T as on .

How to invest in Can-Fite BioPharma Stock (CANF) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Can-Fite BioPharma on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Can-Fite BioPharma Stock (CANF) from India?

Indian investors can start investing in Can-Fite BioPharma (CANF) shares with as little as ₹94.9000015258789 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.00 in Can-Fite BioPharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Can-Fite BioPharma share’s latest price of $1.63 as on November 3, 2026 at 8:45 am IST, you will get 6.1350 shares of Can-Fite BioPharma. Learn more about fractional shares .

What are the returns that Can-Fite BioPharma has given to Indian investors in the last 5 years?

Can-Fite BioPharma stock has given -99.45% share price returns and 27.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?